Defining Fingerprint Pattern of Cardiotoxicity
and Targeting Specific Underlying Mechanisms
of Cardiotoxicity Could be the Way for Successful
Cardioprotective Measures in Paediatric Cancer
Patients Treated with Anthracyclines

Amani E Khalifa'>
  <meta name=

Review Article

Defining Fingerprint Pattern of Cardiotoxicity and Targeting Specific Underlying Mechanisms of Cardiotoxicity Could be the Way for Successful Cardioprotective Measures in Paediatric Cancer Patients Treated with Anthracyclines

Amani E Khalifa*

Faculty of Pharmacy, Ain Shams University, Egypt

Corresponding Author

Received Date: September 07, 2018; Published Date: November, 01, 2018

Abstract

Anthracycline Chemotherapy are administered to more than 50% of children with cancer and up to 60% of those treated with an anthracycline will develop echocardiographic abnormalities [1]. Compare to their siblings, childhood cancer survivors (CCSs) have a 15-fold increased risk of developing congestive heart failure (CHF) and mortality rate in those with CHF approaches 50% [2]. Once anthracycline-induced cardiomyopathy develops, it is commonly progressive, with no definitive treatment other than implantation of a left ventricular assist device and/or heart transplantation [3,4]. Cardiac disease is the third leading cause of premature death in CCSs after cancer recurrence and second malignancies [5]. Early medical intervention can improve parameters of cardiotoxicity; the most feared complication of anthracycline chemotherapy [6].

Article Details

Citation

Amani E Khalifa. Defining Fingerprint Pattern of Cardiotoxicity and Targeting Specific Underlying Mechanisms of Cardiotoxicity Could be the Way for Successful Cardioprotective Measures in Paediatric Cancer Patients Treated with Anthracyclines. Adv Can Res & Clinical Imag. 1(2): 2018. ACRCI.MS.ID.000506.